alexa Intellectual Property And Regulatory Interplay In Biosimilars
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

7th European Biosimilars Congress
May 15-16, 2017 Munich, Germany

Christoph Volpers
Michalski Hüttermann & Partner, Germany
Keynote: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-025
Driven by strong, albeit diverging interests of various stakeholders like pharmaceutical companies, legislators, health care providers and patient interest groups, the global biosimilar market is expected to reach more than US-$ 40 billion by mid of the next decade. Whereas, the regulatory pathway for biosimilars in Europe has been validated and refined over the last ten years, the US is still struggling for guidance and interpretation of its biosimilars legislation where regulatory and patent issues are much more connected. The talk will give an update on recent case law in this field and discuss strategic implications from various perspectives.

Christoph Volpers has done his PhD in Molecular Biology from the University of Mainz, Germany, and an MBA from Bradford University, UK. He has almost 15 years of experience in Intellectual Property and Licensing. Before he joined the patent law firm, Michalski Hüttermann & Partners, Dusseldorf/Munich, as Senior Patent Consultant in early 2015, he was the Director IP Biologics of the Teva Pharmaceutical Industries for six years with global responsibility for innovative biologics and biosimilar products. He is the Founder of a biopharmaceutical consultancy firm, author of more than 20 publications and a member of the Licensing Executive Society.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version